Published in Biophys J on January 01, 2001
The Alzheimer's peptides Abeta40 and 42 adopt distinct conformations in water: a combined MD / NMR study. J Mol Biol (2007) 2.35
Amyloid beta-protein monomer structure: a computational and experimental study. Protein Sci (2006) 1.99
Polymorphism in Alzheimer Abeta amyloid organization reflects conformational selection in a rugged energy landscape. Chem Rev (2010) 1.62
Structure and dynamics of the Abeta(21-30) peptide from the interplay of NMR experiments and molecular simulations. J Am Chem Soc (2008) 1.47
Linking folding with aggregation in Alzheimer's beta-amyloid peptides. Proc Natl Acad Sci U S A (2007) 1.42
Effects of familial Alzheimer's disease mutations on the folding nucleation of the amyloid beta-protein. J Mol Biol (2008) 1.24
Charge states rather than propensity for beta-structure determine enhanced fibrillogenesis in wild-type Alzheimer's beta-amyloid peptide compared to E22Q Dutch mutant. Protein Sci (2002) 1.19
Homogeneous and heterogeneous tertiary structure ensembles of amyloid-β peptides. Biochemistry (2011) 1.19
Principles governing oligomer formation in amyloidogenic peptides. Curr Opin Struct Biol (2010) 1.14
Differences in β-strand populations of monomeric Aβ40 and Aβ42. Biophys J (2013) 1.08
Probing the origins of increased activity of the E22Q "Dutch" mutant Alzheimer's beta-amyloid peptide. Biophys J (2001) 1.06
Plasticity of influenza haemagglutinin fusion peptides and their interaction with lipid bilayers. Biophys J (2004) 1.06
Transmembrane structures of amyloid precursor protein dimer predicted by replica-exchange molecular dynamics simulations. J Am Chem Soc (2009) 1.04
Investigating how peptide length and a pathogenic mutation modify the structural ensemble of amyloid beta monomer. Biophys J (2012) 1.02
Simulating oligomerization at experimental concentrations and long timescales: A Markov state model approach. J Chem Phys (2008) 1.02
Structures and free-energy landscapes of the wild type and mutants of the Abeta(21-30) peptide are determined by an interplay between intrapeptide electrostatic and hydrophobic interactions. J Mol Biol (2008) 1.01
Structures of beta-amyloid peptide 1-40, 1-42, and 1-55-the 672-726 fragment of APP-in a membrane environment with implications for interactions with gamma-secretase. J Am Chem Soc (2009) 0.98
Impact of the mutation A21G (Flemish variant) on Alzheimer's beta-amyloid dimers by molecular dynamics simulations. Biophys J (2006) 0.96
Spontaneous fibril formation by polyalanines; discontinuous molecular dynamics simulations. J Am Chem Soc (2006) 0.94
Nature of the amyloid-beta monomer and the monomer-oligomer equilibrium. J Biol Chem (2011) 0.94
The stability and dynamics of the human calcitonin amyloid peptide DFNKF. Biophys J (2004) 0.92
Phase diagrams describing fibrillization by polyalanine peptides. Biophys J (2004) 0.90
Molecular nonlinear dynamics and protein thermal uncertainty quantification. Chaos (2014) 0.85
Side-chain hydrophobicity and the stability of Aβ₁₆₋₂₂ aggregates. Protein Sci (2012) 0.85
The concentration of soluble extracellular amyloid-β protein in acute brain slices from CRND8 mice. PLoS One (2010) 0.84
A structural model of polyglutamine determined from a host-guest method combining experiments and landscape theory. Biophys J (2004) 0.84
Discriminating early stage A{beta}42 monomer structures using chirality-induced 2DIR spectroscopy in a simulation study. Proc Natl Acad Sci U S A (2010) 0.84
Dynamic properties of pH-dependent structural organization of the amyloidogenic beta-protein (1-40). Prion (2009) 0.81
Benchmarking implicit solvent folding simulations of the amyloid beta(10-35) fragment. J Phys Chem B (2008) 0.80
Stability of transmembrane amyloid β-peptide and membrane integrity tested by molecular modeling of site-specific Aβ42 mutations. PLoS One (2013) 0.79
Tracking the mechanism of fibril assembly by simulated two-dimensional ultraviolet spectroscopy. J Phys Chem A (2013) 0.78
Reversibility of beta-amyloid self-assembly: effects of pH and added salts assessed by fluorescence photobleaching recovery. Biomacromolecules (2010) 0.77
Thermodynamically stable amyloid-β monomers have much lower membrane affinity than the small oligomers. Front Physiol (2013) 0.77
Exploring the role of hydration and confinement in the aggregation of amyloidogenic peptides Aβ(16-22) and Sup35(7-13) in AOT reverse micelles. J Chem Phys (2014) 0.76
Characterization of the internal dynamics and conformational space of zinc-bound amyloid β peptides by replica-exchange molecular dynamics simulations. Eur Biophys J (2013) 0.76
Arginine and disordered amyloid-β peptide structures: molecular level insights into the toxicity in Alzheimer's disease. ACS Chem Neurosci (2013) 0.75
The interpretation of protein structures: estimation of static accessibility. J Mol Biol (1971) 40.24
Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate. J Biol Chem (1997) 5.07
Amyloid fibrillogenesis: themes and variations. Curr Opin Struct Biol (2000) 4.76
On the nucleation and growth of amyloid beta-protein fibrils: detection of nuclei and quantitation of rate constants. Proc Natl Acad Sci U S A (1996) 4.75
Observation of metastable Abeta amyloid protofibrils by atomic force microscopy. Chem Biol (1997) 4.16
Solution conformations and aggregational properties of synthetic amyloid beta-peptides of Alzheimer's disease. Analysis of circular dichroism spectra. J Mol Biol (1992) 3.53
Kinetic theory of fibrillogenesis of amyloid beta-protein. Proc Natl Acad Sci U S A (1997) 3.40
Alzheimer's disease: a central role for amyloid. J Neuropathol Exp Neurol (1994) 3.19
Atomic force microscopic imaging of seeded fibril formation and fibril branching by the Alzheimer's disease amyloid-beta protein. Chem Biol (1997) 3.05
Atomic solvation parameters applied to molecular dynamics of proteins in solution. Protein Sci (1992) 3.05
The Alzheimer's peptide a beta adopts a collapsed coil structure in water. J Struct Biol (2000) 2.26
Mapping of the spectral densities of N-H bond motions in eglin c using heteronuclear relaxation experiments. Biochemistry (1992) 1.91
Temperature dependence of amyloid beta-protein fibrillization. Proc Natl Acad Sci U S A (1998) 1.78
Point substitution in the central hydrophobic cluster of a human beta-amyloid congener disrupts peptide folding and abolishes plaque competence. Biochemistry (1996) 1.58
Structural and kinetic features of amyloid beta-protein fibrillogenesis. Amyloid (1998) 1.50
1H NMR of A beta amyloid peptide congeners in water solution. Conformational changes correlate with plaque competence. Biochemistry (1995) 1.48
Frequency spectrum of NH bonds in eglin c from spectral density mapping at multiple fields. Biochemistry (1995) 1.29
Brain amyloid--a physicochemical perspective. Brain Pathol (1996) 1.27
Deposition of monomeric, not oligomeric, Abeta mediates growth of Alzheimer's disease amyloid plaques in human brain preparations. Biochemistry (1999) 1.27
Activation barriers to structural transition determine deposition rates of Alzheimer's disease a beta amyloid. J Struct Biol (2000) 1.20
In vitro growth of Alzheimer's disease beta-amyloid plaques displays first-order kinetics. Biochemistry (1996) 1.19
Residual structure in the Alzheimer's disease peptide: probing the origin of a central hydrophobic cluster. Fold Des (1998) 1.02
Regulation of pancreatic beta-cell growth and survival by the serine/threonine protein kinase Akt1/PKBalpha. Nat Med (2001) 4.07
Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model. Science (2000) 3.12
Folding transition in the DNA-binding domain of GCN4 on specific binding to DNA. Nature (1990) 2.97
Alzheimer's disease amyloid propagation by a template-dependent dock-lock mechanism. Biochemistry (2000) 2.37
The Alzheimer's peptide a beta adopts a collapsed coil structure in water. J Struct Biol (2000) 2.26
Novel methods of sampling phase space in the simulation of biological systems. Curr Opin Struct Biol (1997) 1.93
Purification of the enzyme reducing bisulfite to trithionate from Desulfovibrio gigas and its identification as desulfoviridin. Biochem Biophys Res Commun (1971) 1.81
Point substitution in the central hydrophobic cluster of a human beta-amyloid congener disrupts peptide folding and abolishes plaque competence. Biochemistry (1996) 1.58
Isolation of a new pigment, desulforubidin, from Desulfovibrio desulfuricans (Norway strain) and its role in sulfite reduction. J Bacteriol (1973) 1.43
Spag4, a novel sperm protein, binds outer dense-fiber protein Odf1 and localizes to microtubules of manchette and axoneme. Dev Biol (1999) 1.42
Review of the inverse Knapp procedure: indications, effectiveness and results. Eye (Lond) (2001) 1.39
Energy landscape theory for Alzheimer's amyloid beta-peptide fibril elongation. Proteins (2001) 1.37
Internal mobility in the partially folded DNA binding and dimerization domains of GAL4: NMR analysis of the N-H spectral density functions. Biochemistry (1996) 1.35
Development of novel statistical potentials for protein fold recognition. Curr Opin Struct Biol (2004) 1.33
Isolation of assimilatroy- and dissimilatory-type sulfite reductases from Desulfovibrio vulgaris. J Bacteriol (1973) 1.28
Deposition of monomeric, not oligomeric, Abeta mediates growth of Alzheimer's disease amyloid plaques in human brain preparations. Biochemistry (1999) 1.27
Calpains play a role in insulin secretion and action. Diabetes (2001) 1.25
Vibrational population relaxation of carbon monoxide in the heme pocket of photolyzed carbonmonoxy myoglobin: comparison of time-resolved mid-IR absorbance experiments and molecular dynamics simulations. Proc Natl Acad Sci U S A (1999) 1.24
The SHAPES strategy: an NMR-based approach for lead generation in drug discovery. Chem Biol (1999) 1.24
Characterization of the major brain osmolytes that accumulate in salt-loaded rats. Am J Physiol (1989) 1.21
Activation barriers to structural transition determine deposition rates of Alzheimer's disease a beta amyloid. J Struct Biol (2000) 1.20
In vitro growth of Alzheimer's disease beta-amyloid plaques displays first-order kinetics. Biochemistry (1996) 1.19
Extraocular muscle surgery in myasthenia gravis. Br J Ophthalmol (1991) 1.15
A study of vibrational relaxation of B-state carbon monoxide in the heme pocket of photolyzed carboxymyoglobin. Biophys J (1999) 1.14
Detection and characterization of a phospholactoyl-enzyme adduct in the reaction catalyzed by UDP-N-acetylglucosamine enolpyruvoyl transferase, MurZ. Biochemistry (1994) 1.13
Causes and outcomes for patients presenting with diplopia to an eye casualty department. Eye (Lond) (2006) 1.12
Mutant superoxide dismutase-1-linked familial amyotrophic lateral sclerosis: molecular mechanisms of neuronal death and protection. J Neurosci (1997) 1.09
The effects of strabismus surgery on anterior segment circulation. Eye (Lond) (1989) 1.09
Probing the mechanisms of fibril formation using lattice models. J Chem Phys (2008) 1.08
Probing the origins of increased activity of the E22Q "Dutch" mutant Alzheimer's beta-amyloid peptide. Biophys J (2001) 1.06
Elevating the hypotropic globe. Br J Ophthalmol (1986) 1.06
An iron tetrahydroporphyrin prosthetic group common to both assimilatory and dissimilatory sulfite reductases. Biochem Biophys Res Commun (1973) 1.05
Treatment of strabismus in adults with botulinum toxin A. Br J Ophthalmol (1985) 1.05
Botulinum toxin A induced protective ptosis. Eye (Lond) (1987) 1.04
Mutation analysis of PTEN/MMAC1 in acute myeloid leukemia. Am J Hematol (2000) 1.04
The Saccharomyces cerevisiae SPT14 gene is essential for normal expression of the yeast transposon, Ty, as well as for expression of the HIS4 gene and several genes in the mating pathway. Mol Gen Genet (1991) 1.04
Role of botulinum toxin A in surgically overcorrected exotropia. J AAPOS (1999) 1.04
Factors governing fibrillogenesis of polypeptide chains revealed by lattice models. Phys Rev Lett (2010) 1.03
Evidence for the involvement of non-heme iron in the active site of hydrogenase from Desulfovibrio vulgaris. Biochim Biophys Acta (1971) 1.03
Sonographic findings of placental lacunae and the prediction of adherent placenta in women with placenta previa totalis and prior Cesarean section. Ultrasound Obstet Gynecol (2006) 1.03
Apolipoprotein A-I domains involved in lecithin-cholesterol acyltransferase activation. Structure:function relationships. J Biol Chem (1993) 1.02
Residual structure in the Alzheimer's disease peptide: probing the origin of a central hydrophobic cluster. Fold Des (1998) 1.02
Recovery of anterior segment circulation after strabismus surgery in adult patients. Ophthalmology (1992) 1.01
Aetiology and management of the 'detached' rectus muscle. Br J Ophthalmol (1992) 1.01
RING-dependent tumor suppression and G2/M arrest induced by the TRC8 hereditary kidney cancer gene. Oncogene (2006) 1.01
Solution structure of core binding factor beta and map of the CBF alpha binding site. Nat Struct Biol (1999) 1.01
Molecular dynamics simulation of NO recombination to myoglobin mutants. J Biol Chem (1993) 1.01
The incidence of strabismus and refractive error in patients with blepharophimosis, ptosis and epicanthus inversus syndrome (BPES). Strabismus (2003) 1.00
Antifungal activity of magnolol and honokiol. Arch Pharm Res (2000) 0.99
Cyclic strabismus without binocular function. J Pediatr Ophthalmol Strabismus (1993) 0.99
Active management in patients with ocular manifestations of myasthenia gravis. Eye (Lond) (2001) 0.98
Enzyme production of Trichoderma reesei Rut C-30 on various lignocellulosic substrates. Appl Biochem Biotechnol (2000) 0.96
Treatment of sixth nerve palsy in adults with combined botulinum toxin chemodenervation and surgery. Ophthalmology (1988) 0.96
Management of ipsilateral ptosis with hypotropia. Br J Ophthalmol (1986) 0.94
The use of botulinum toxin for treatment of acquired nystagmus and oscillopsia. Ophthalmology (1994) 0.93
Intensive occlusion therapy for amblyopia. Br J Ophthalmol (2001) 0.93
Botulinum toxin in fourth nerve palsies. Aust N Z J Ophthalmol (1997) 0.93
Botulinum toxin A-induced protective ptosis in corneal disease. Ophthalmology (1988) 0.93
Intragenic suppression of a luxR mutation: characterization of an autoinducer-independent LuxR. FEMS Microbiol Lett (1995) 0.92
Persisting hypotropias following protective ptosis induced by botulinum neurotoxin. Eye (Lond) (1994) 0.91
Continuous anisotropic representation of coarse-grained potentials for proteins by spherical harmonics synthesis. J Mol Graph Model (2004) 0.91
Isolation of a protein containing tightly bound 5-methoxybenzimidazolylcobamide (factor 3m) from Clostridium thermoaceticum. Biochemistry (1973) 0.91
Cytotoxic triterpenes from Crataegus pinnatifida. Arch Pharm Res (2000) 0.90
Long-term results of botulinum toxin in consecutive and secondary exotropia: outcome in patients initially treated with botulinum toxin. J AAPOS (1998) 0.89
Chorioretinal scarring following the Faden operation. A retrospective study of 100 procedures. Eye (Lond) (1989) 0.89
Results of superior oblique posterior tenotomy. J AAPOS (1998) 0.89
Reactivity of Desulfovibrio gigas hydrogenase toward artificial and natural electron donors or acceptors. Biochimie (1978) 0.89
Segmental colonic dilatation in a neonate. J Pediatr Surg (1992) 0.89
Binocular diplopia in unilateral aphakia: the role of botulinum toxin. Eye (Lond) (1991) 0.89
Direct computation of long time processes in peptides and proteins: reaction path study of the coil-to-helix transition in polyalanine. Proteins (1999) 0.88
Residual symptomatic superior oblique palsy. Strabismus (2007) 0.88
Botulinum toxin therapy in dysthyroid strabismus. Eye (Lond) (1990) 0.88
Phacoemulsification and opaque intraocular lens implantation for the treatment of intractable diplopia. Ophthalmic Surg Lasers (2001) 0.87
Morphological effects of ArF excimer laser irradiation on enamel and dentin. Lasers Surg Med (1997) 0.87
Further studies on the biosynthesis of chlorothricin. J Antibiot (Tokyo) (1986) 0.87
Changing the inhibitory specificity and function of the proteinase inhibitor eglin c by site-directed mutagenesis: functional and structural investigation. Biochemistry (1992) 0.86
Disinsertion of the inferior oblique muscle for treatment of superior oblique paresis. J Pediatr Ophthalmol Strabismus (2001) 0.85
Dissecting contact potentials for proteins: relative contributions of individual amino acids. Proteins (2008) 0.85
A scoring method for Hess charts. Eye (Lond) (1992) 0.84
The diagnosis and surgical management of acquired bilateral superior oblique palsy. Eye (Lond) (1987) 0.84
Herpesvirus saimiri-induced lymphoblastoid rabbit cell line: growth characteristics, virus persistence, and oncogenic properties. J Virol (1985) 0.84
Duane's retraction syndrome and juvenile Batten's disease: a new association? Aust N Z J Ophthalmol (1998) 0.84
Use of augmented Lagrangians in the calculation of molecular conformations by distance geometry. J Chem Inf Comput Sci (1988) 0.84
Management of strabismus due to orbital myositis. Eye (Lond) (1995) 0.83
New antimicrobial flavanones from Physena madagascariensis. J Nat Prod (2000) 0.83
Ocular motility disturbances after surgery for retinal detachment. J AAPOS (1998) 0.82
Identification of the effects of aging-related gene-matrix metalloproteinase on allograft outcomes in kidney transplantation. Transplant Proc (2013) 0.82
Studies on the biosynthesis of the alpha-glucosidase inhibitor acarbose: valienamine, a m-C7N unit not derived from the shikimate pathway. J Antibiot (Tokyo) (1987) 0.81
Management of diplopia on down-gaze following orbital trauma. Eye (Lond) (1990) 0.81
Congenital anomalies in patients with Duane retraction syndrome and their relatives. J AAPOS (2000) 0.81
Botulinum toxin in childhood strabismus. Strabismus (1999) 0.81
Complete transection of the common bile duct due to blunt ranuma. Ann Surg (1974) 0.80
Mutation analysis of PTEN/MMAC 1 in sporadic thyroid tumors. Kaohsiung J Med Sci (2000) 0.80
Baclofen for patients with congenital periodic alternating nystagmus. Strabismus (2006) 0.80
Restoration of cytotoxic T lymphocyte function in malignant pleural effusion: interleukin-15 vs. interleukin-2. J Interferon Cytokine Res (2000) 0.79
Management of VIth nerve palsy--avoiding unnecessary surgery. Eye (Lond) (1992) 0.79
Superior oblique myokymia. A possible etiologic factor. Arch Ophthalmol (1984) 0.79
Bilateral consecutive superior oblique palsy following fronto-ethmoidal sinusitis. J Pediatr Ophthalmol Strabismus (1991) 0.78